TFRC and lysosomal storage disease: Conjugation of TfR mAbs with enzymes (e.g., β galactosidase-1, iduronate-2-sulfatase) has been investigated for their use in enzyme replacement therapy in lysosomal disorders (e.g., Niemann-Pick disease) [52].